Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

首页> 外文期刊>Intelligence: A Multidisciplinary Journal >Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

【24h】

Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

机译：帕尔巴昔米利夫驯民（血吸虫）和everolimus-- exemestane（Eve-EXE）用于二叶组织学的转移性乳腺癌（MBC）的第二线激素治疗（HT）：倾向得分匹配分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Intelligence: A Multidisciplinary Journal》 |2020年第2020期|共3页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类心理学;
关键词

相似文献

外文文献
专利

1. Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：帕尔巴昔米利夫驯民（血吸虫）和everolimus-- exemestane（Eve-EXE）用于二叶组织学的转移性乳腺癌（MBC）的第二线激素治疗（HT）：倾向得分匹配分析
2. Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis [J] . Pons-Tostivint Elvire, Kirova Youlia, Lusque Amelie, Annals of surgical oncology . 2019,第2期

机译：大型多中心队列研究德诺型转移性乳腺癌原发性肿瘤局部肿瘤的生存影响：倾向分数分析
3. Effect of Bevacizumab and Eribulin for metastatic breast cancer in the real world evaluated using the propensity score matching analysis (PSMA) and inverse probability of treatment weighting analysis (IPTWA) [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：使用倾向评分匹配分析（PSMA）和治疗加权分析的逆概率评估贝伐单抗和叶英蛋白在真实世界中转移乳腺癌的影响及治疗加权分析（IPTWA）
4. Cost-Benefit Analysis of Nanoparticle Albumin-Bound Paclitaxel versus Solvent-Based Paclitaxel for the Treatment of Metastatic Breast Cancer in the United States [D] . Vichansavakul, Kittaya 2013

机译：纳米白蛋白结合紫杉醇与溶剂型紫杉醇在美国治疗转移性乳腺癌的成本效益分析
5. Palbociclib Plus Fulvestrant or Everolimus Plus Exemestane for Pretreated Advanced Breast Cancer with Lobular Histotype in ER+/HER2− Patients: A Propensity Score-Matched Analysis of a Multicenter Retrospective Patient Series [O] . Armando Orlandi, Elena Iattoni, Laura Pizzuti, 2020

机译：Palbociclib加上富勒司或埃弗洛米斯加上预处理的晚期乳腺癌的exemestane用r + / Her2-患者的小叶组型：多中心回顾性患者系列的倾向分数分析
6. Presentation and Survival by Hormonal Receptor Status in Metaplastic Breast Cancer: A Propensity Score-matched Analysis [O] . Siqin Wang, Jin Hu, yanting Zhang, 2021

机译：血液抑制乳腺癌中荷尔蒙受体状态的介绍和生存：倾向分数匹配分析

Palbociclib-fulvestrant (PALBO-FUL) and everolimus-exemestane (EVE-EXE) for second line hormonal treatment (HT) of metastatic breast cancer (MBC) with lobular histology: A propensity score matched analysis

著录项

引文网络

相似文献

相关主题

期刊订阅